[HTML][HTML] Berberine: An inspiring resource for the treatment of colorectal diseases
F Cao, W Xia, S Dai, C Wang, R Shi, Y Yang… - Biomedicine & …, 2023 - Elsevier
Colorectal cancer is a prevalent malignant tumor with a complex and diverse pathogenesis.
In recent years, natural products have shown promising application prospects as sources of …
In recent years, natural products have shown promising application prospects as sources of …
Genome-scale CRISPR-Cas9 screening in stem cells: theories, applications and challenges
Due to the rapid development of stem cell technology, there have been tremendous
advances in molecular biological and pathological research, cell therapy as well as …
advances in molecular biological and pathological research, cell therapy as well as …
[HTML][HTML] Suppression of alpha-tubulin acetylation potentiates therapeutic efficacy of Eribulin in liver cancer
Y Zhong, C Wang, Y Wang, Y Wu, H Wang… - American Journal of …, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is a prevalent cancer with limited effective treatments.
Eribulin mesylate is a novel chemotherapy drug that inhibits microtubule elongation and …
Eribulin mesylate is a novel chemotherapy drug that inhibits microtubule elongation and …
[HTML][HTML] Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer
S Nemours, C Solé, I Goicoechea, M Armesto… - International Journal of …, 2024 - mdpi.com
Paclitaxel is a widely used chemotherapeutic agent for the treatment of breast cancer (BC),
including as a front-line treatment for triple-negative breast cancer (TNBC) patients …
including as a front-line treatment for triple-negative breast cancer (TNBC) patients …
Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single …
W Huang, C Wang, L Wang, Y Shen, Q Chen… - Frontiers in Cell and …, 2024 - frontiersin.org
Background: Patients with Triple-negative breast cancer (TNBC) face a poor prognosis and
limited therapeutic options. Current data on eribulin usage to treat TNBC is scarce …
limited therapeutic options. Current data on eribulin usage to treat TNBC is scarce …
[HTML][HTML] 真实世界艾立布林治疗HER2 阴性转移性乳腺癌的疗效及安全性分析
吴昕煜， 黄香 - 南京医科大学学报(自然科学版), 2023 - jnmu.njmu.edu.cn
目的: 探讨以艾立布林为基础的治疗方案在真实世界治疗HER2 阴性转移性乳腺癌的临床疗效及
安全性. 方法: 本研究回顾性分析2020 年1 月—2021 年11 月南京医科大学附属医院肿瘤内科 …
安全性. 方法: 本研究回顾性分析2020 年1 月—2021 年11 月南京医科大学附属医院肿瘤内科 …